<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002155</url>
  </required_header>
  <id_info>
    <org_study_id>246E</org_study_id>
    <secondary_id>039</secondary_id>
    <nct_id>NCT00002155</nct_id>
  </id_info>
  <brief_title>A Six-Month Safety and Antiviral Study in HIV-1 Seropositive, AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cells/mm3 to Evaluate MK-639 Alone Versus Zidovudine (AZT) and 3TC Versus the Combination of MK-639 With AZT/3TC</brief_title>
  <official_title>A Six-Month Safety and Antiviral Study in HIV-1 Seropositive, AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cells/mm3 to Evaluate MK-639 Alone Versus Zidovudine (AZT) and 3TC Versus the Combination of MK-639 With AZT/3TC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To compare effects on CD4 counts and serum viral RNA among HIV-seropositive, zidovudine&#xD;
      (AZT)-experienced patients in three treatment arms: indinavir sulfate ( MK-639; Crixivan )&#xD;
      plus AZT plus lamivudine ( 3TC ) versus MK-639 alone versus AZT/3TC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AZT-experienced patients are randomized to receive MK-639/AZT/3TC or MK-639 alone or AZT/3TC.&#xD;
      Additionally, patients who have received &lt; 6 months of AZT or who are intolerant but received&#xD;
      prior 3TC or who require concomitant rifampin therapy may receive open-label MK-639.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>600</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indinavir sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed for all patients:&#xD;
&#xD;
          -  Standard prophylaxis for opportunistic infections.&#xD;
&#xD;
          -  Continuation of treatment for opportunistic infection.&#xD;
&#xD;
        Allowed for open-label study patients:&#xD;
&#xD;
          -  Rifampin.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV positivity.&#xD;
&#xD;
          -  CD4 count &lt;= 50 cells/mm3.&#xD;
&#xD;
          -  More than 6 months of prior AZT (blinded study only).&#xD;
&#xD;
        NOTE:&#xD;
&#xD;
          -  Patients on the open-label study must have AZT intolerance or have &lt; 6 months of prior&#xD;
             AZT.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Required for blinded study patients:&#xD;
&#xD;
          -  &gt; 6 months of prior AZT.&#xD;
&#xD;
        Required for open-label study patients:&#xD;
&#xD;
          -  &lt; 6 months of prior AZT.&#xD;
&#xD;
        Allowed for open-label study patients:&#xD;
&#xD;
          -  Prior 3TC.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded in all patients:&#xD;
&#xD;
          -  Immunosuppressants.&#xD;
&#xD;
        Excluded in blinded study patients:&#xD;
&#xD;
          -  AZT, ddI, ddC, or d4T.&#xD;
&#xD;
          -  Rifampin.&#xD;
&#xD;
        Excluded in open-label study patients:&#xD;
&#xD;
          -  3TC.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded in all patients:&#xD;
&#xD;
          -  Prior protease inhibitors.&#xD;
&#xD;
          -  Investigational agents and immunomodulators within 30 days prior to study entry.&#xD;
&#xD;
          -  Immunosuppressants within 2 weeks prior to study entry.&#xD;
&#xD;
        Excluded in blinded study patients:&#xD;
&#xD;
          -  Any prior 3TC.&#xD;
&#xD;
          -  AZT, ddI, ddC, or d4T within 2 weeks prior to study entry.&#xD;
&#xD;
        Excluded in open-label study patients:&#xD;
&#xD;
        3TC within 30 days prior to study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Merck &amp; Co Inc</name>
      <address>
        <city>Whitehouse Station</city>
        <state>New Jersey</state>
        <zip>088890100</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA, Chodakewitz JA. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997 Sep 11;337(11):734-9. doi: 10.1056/NEJM199709113371102.</citation>
    <PMID>9287228</PMID>
  </reference>
  <reference>
    <citation>Hirsch M, Steigbigel R, Staszewski S, Mellors J, Scerpella E, Hirschel B, Lange J, Squires K, Rawlins S, Meibohm A, Leavitt R. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy. J Infect Dis. 1999 Sep;180(3):659-65. doi: 10.1086/314948.</citation>
    <PMID>10438352</PMID>
  </reference>
  <verification_date>June 1996</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Antiviral Agents</keyword>
  <keyword>Zidovudine</keyword>
  <keyword>HIV Protease Inhibitors</keyword>
  <keyword>Lamivudine</keyword>
  <keyword>Indinavir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Indinavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

